Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive telisotuzumab vedotin every 2 weeks via intravenous (IV) infusion. In the Active Comparator Arm, participants will receive docetaxel every 3 weeks via IV infusion.